A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer.

Trial Profile

A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Goserelin; Triptorelin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms SOFT
  • Most Recent Events

    • 05 Jun 2018 Results assessing absolute improvements in freedom from distant recurrence in patients from SOFT and TEXT trials (n=4891), presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Results assessing absolute improvements in freedom from distant recurrence in patients from SOFT and TEXT trials presented in a Dana-Farber Cancer Institute media release.
    • 04 Jun 2018 Results of the updated analysis of SOFT and TEXT trials, published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top